98results about How to "Increase bone formation" patented technology

Disclosed are compositions and methods for augmenting bone formation by administering isolated human mesenchymal stem cells (hMSCs) with a ceramic material or matrix or by administering hMSCs; fresh, whole marrow; or combinations thereof in a resorbable biopolymer which supports their differentiation into the osteogenic lineage. Contemplated is the delivery of (i) isolated, culture-expanded, human mesenchymal stem cells; (ii) freshly aspirated bone marrow; or (iii) their combination in a carrier material or matrix.

A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and glucosamine sulfate, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.

Methods of treatment of various bone indications, such as osteoporosis, in a mammal are provided wherein an effective amount of an antagonist that binds to a B-cell surface marker, such as a CD20 antibody, is administered, optionally also with another medicament such as an agent that treats such disorders in an effective amount. Articles of manufacture are also provided. Further, a method of inhibiting osteolysis in a mammal is provided comprising introducing into said mammal an isolated odontoprogenitor or osteoprogenitor cell comprising a nucleic acid encoding an antibody that binds to a B-cell surface marker.

The invention is directed to a method of inhibiting bone resorption. The method comprises administering to a human an amount of sclerostin inhibitor that reduces a bone resorption marker level for at least 2 weeks. The invention also provides a method of monitoring anti-sclerostin therapy comprising measuring one or more bone resorption marker levels, administering a sclerostin binding agent, then measuring the bone resorption marker levels. Also provided is a method of increasing bone mineral density; a method of ameliorating the effects of an osteoclast-related disorder; a method of treating a bone-related disorder by maintaining bone density; and a method of treating a bone-related disorder in a human suffering from or at risk of hypocalcemia or hypercalcemia, a human in which treatment with a parathyroid hormone or analog thereof is contraindicated, or a human in which treatment with a bisphosphonate is contraindicated.

A porous composite comprising a porous layer containing a calcium phosphate ceramic, and a dense layer formed on part of the porous layer and having a smaller average pore size than that of the porous layer. The porous composite can be produced by (1) introducing a slurry containing a calcium phosphate ceramic / collagen composite and collagen into a molding die having a high thermal conductivity, (2) rapidly freezing and drying the slurry in the molding die, to form a porous body comprising a porous layer and a dense layer formed on the porous layer, (3) cross-linking collagen in the porous body, and (4) removing the dense layer except for a portion thereof on a surface coming into contact with a soft tissue when implanted in a human body, so that the porous layer is exposed.

A bite plate allowing for contact with occlusal and facial and / or lingual maxillary and mandibular teeth is coupled to an extraoral housing containing a rechargeable battery coupled to a vibrator coupled to a processor coupled to data and charging port or ports. The housing is at least water resistant, and a hatch allows access to the data and charging port or ports only. The device is fitted with a very smooth and quiet vibrator, with minimal variance on operating specifications.

Bone fixation or augmentation in a mammalian body to enhance the mechanical strength of a fracture is provided by reinforcement fixing bone ends together using the implant device. A resorbable device can be rendered anti-osteolytic by incorporating materials such as bisphosphonates. It can also be rendered osteoconductive by the incorporation of an osteoconductive material such as bioactive glass or TCP. The implant device has a matrix as one phase, where the matrix is made of a bioresorbable polymer. One phase of the implant is made from self-reinforcing elements and the matrix contains an antiosteolytic agent component. The implant contains further osteoconductive and / or osteoconductive material.

Methods and compositions are provided for the therapeutic use of Wnt proteins, for enhancing bone growth and regeneration, including repair following injury, osseointegration of implants, and the like. In some embodiments of the invention, the compositions are administered locally, e.g. by injection at the site of an injury. For certain conditions it is desirable to provide Wnt activity for short periods of time, and an effective dose will be administered over a defined, short period of time.

The present invention provides a composite implant comprising pores of a porous structure filled with a biodegradable magnesium-based alloy. Further, the present invention provides a composite implant which filles pores of the porous structure prepared by a metal, a ceramic or a polymer with a biodegradable magnesium-based alloy. Mechanical properties of the composite implant of the present invention are improved because a magnesium-based alloy filled in its pores increases the strength of a porous structure comprised of a metal, a ceramic or a polymer. Further, it can be expected that the magnesium-based alloy filled in the porous structure is decomposed in a living body, thus increasing bone formation rate. Accordingly bone tissue can be rapidly formed because the composite implant of the present invention has high strength and excellent interfacial force between the composite implant and bone tissue, compared to conventional porous materials.

The invention provides a method for enhancing bone formation, inhibiting osteoclastic differentiation and / or activating osteoblastic differentiation whereby to manage, treat or achieve prophylaxis of bone disease which comprises administering to a human or animal subject suffering from, or susceptible to bone disease a therapeutically or prophylactically effective amount of a lanthanum compound.

Amine polymers, particularly aliphatic amine polymers, are useful in the treatment and prevention of bone disease and in methods for promoting bone formation. Sevelemer, polyallylamine crosslinked with epichlorohydrin, which is sold under the tradename Renagel®, is the preferred polymer used in the invention.

A bone grafting material, a method of producing the same, and an implant. The bone grafting material comprises a porous carrier of ceramic or glass ceramic or glass material and at least one pyrrolidone arranged in the carrier.

Disclosed herein is a non-toxic, bioresorbable, magnesium based alloy for use in production of implants. Specifically exemplified herein are alloy embodiments useful for orthopedic implants. Also disclosed are alloy materials that incorporate magnesium, calcium and strontium.

Disclosed herein is a matrix for inducing or enhancing osteoclast differentiation. The matrix comprises a material having an osteoclastogenic agent associated therewith, the agent being releasable from the material in an amount which is sufficient to induce or enhance osteoclast differentiation.

The present invention relates to a nutritional composition for infants and / or toddlers comprising a lipid component which has a large lipid globule size, having a volume weighted mode diameter above 1.0 μm and / or with a diameter of 2 to 12 μm in a amount of at least 45 volume % based on total lipid. The composition can be used to increase bone mineral content and / or bone mass density, to prevent osteoporosis and / or osteopenia and for the further prevention of obesity.

To identify molecular determinants of lytic bone disease in multiple myeloma, the expression profiles of ˜12,000 genes in CD138-enriched plasma cells from newly diagnosed multiple myeloma patients exhibiting no radiological evidence of lytic lesions (n=28) were compared to those with ≧3 lytic lesions (n=47). Two secreted WNT signaling antagonists, soluble frizzled related protein 3 (SFRP-3 / FRZB) and the human homologue of Dickkopf-1 (DKK1), were expressed in 40 of 47 with lytic bone lesions, but only 16 of 28 lacking bone lesions (P<0.05). DKK1 and FRZB were not expressed in plasma cells from 45 normal bone marrow donors or 10 Waldenstrom's macroglobulinemia, a related plasma cells malignancy that lacks bone disease. These data indicate that these factors are important mediators of multiple myeloma bone disease, and inhibitors of these proteins may be used to block bone disease.

The present invention provides methods for (i) reducing loss of bone mass or bone density, (ii) increasing bone mass or bone density, (iii) maintaining bone mass or bone density, and / or (iv) reducing loss of calcium from bone, comprising: administering to a subject a therapeutically effective amount of an NFAT agonist. The method could be used for treating, preventing or delaying a bone condition. The invention further provides a method for promoting healing of bone fractures or bone defects comprising: administering to a subject a therapeutically effective amount of an NFAT agonist. Compositions comprising NFAT agonists can also be used for the in vitro or in vivo generation of bone tissue. The invention also provides screening methods for agents which promotes, maintains, or reduces the loss of, bone mass, and the use of such agents for therapeutic purposes.

An implant device for stimulating osteogenesis and osseointegration comprises a hollow annular housing member, a pulsed current modulator, and a coil connected to the current modulator. The current modulator and at least a portion of the coil are mounted within the housing member. A frequency of the pulsed current is selected to generate an electromagnetic field of a predetermined flux density that penetrates, and propagates radially outwardly from, the housing member for a sufficiently large propagation distance to stimulate osteogenesis and osseointegration, by means of the generated electromagnetic field, of a bone region in which the implant device is implanted and which is disposed radially outwardly from the housing member.

Methods of using an injectable or implantable rod-shaped formulation for delivery of osteogenic proteins to treat osteoporotic and / or osteopenic bone are disclosed. The formulation comprises hyaluronic acid derivatives and osteogenic proteins, and optional excipients and active ingredients such as a bone resorption inhibitor.

An injectable or implantable rod-shaped formulation is disclosed for delivery of osteogenic proteins. The formulation comprises hyaluronic acid derivatives and osteogenic proteins, and optional excipients and active ingredients such as a bone resorption inhibitor. Methods of making injectable rod-shaped pharmaceutical compositions and methods of using the osteogenic compositions to treat osteoporotic and / or osteopenic bone are also disclosed.

It is intended to provide a dental material formed by using a hydroxy apatite, which is suitable for performing the guided bone regeneration (GBR) method in the implant therapy of dentistry. Also, it is intended to provide a composite dental material which is a bioabsorbable film provided integrally with hydroxy apatite, which is capable of rapidly attracting the osteoblast and blocking the fibroblast. The dental material is a membrane to be used for a guided bone regeneration method of guiding a bone formation by preventing invasion by anaplastic fibroblast by covering a bone developing site with a blocking membrane and filling the bone developing site with osteoblast, wherein a membrane main body of the blocking membrane is formed by using hydroxy apatite having osteoconductive capability of rapidly attracting osteoblast for the purpose of disposing the hydroxy apatite at a bone developing site side of the membrane main body. The composite dental material is a membrane to be used for a guided bone regeneration method of guiding a bone formation by preventing invasion by anaplastic fibroblast by covering a bone developing site with a blocking membrane and filling the bone developing site with osteoblast, wherein a membrane main body of the blocking membrane is formed by using a bioabsorbable membrane, and the bioabsorbable membrane is integrally provided with hydroxy apatite having osteoconductive capability of rapidly attracting osteoblast and a structure of being disposed at a bone developing site side of the membrane main body.

The invention relates to a hydroxylapatite material containing phosphate wherein the microporous structure of algae hard-tissue raw material is retained in the end product and which can be obtained by reacting an organic compound devoid of algae hard-tissue in an alkaline aqueous phosphate solution by adding magnesium ions at an elevated temperature. The invention also relates to a method for the production of said hydroxylapatite material containing tricalcium phosphate, which is characterized in that it is especially well resorbed in the body, is especially suitable as a bone substitute material or as a carrier material for active ingredients. Said material can also be used as a filter material.

The present invention provides methods and compositions for promoting bone regeneration, comprising administration of calmodulin. The method of bone regeneration is applied to subjects having bone disorders characterized by decreased bone mass such as osteopenia and osteoporosis, as well as those suffering from non-union fractures and osteochondrosis.

A porous composite comprising a porous layer containing a calcium phosphate ceramic, and a dense layer formed on part of the porous layer and having a smaller average pore size than that of the porous layer. The porous composite can be produced by (1) introducing a slurry containing a calcium phosphate ceramic / collagen composite and collagen into a molding die having a high thermal conductivity, (2) rapidly freezing and drying the slurry in the molding die, to form a porous body comprising a porous layer and a dense layer formed on the porous layer, (3) cross-linking collagen in the porous body, and (4) removing the dense layer except for a portion thereof on a surface coming into contact with a soft tissue when implanted in a human body, so that the porous layer is exposed.

It is an object of the present invention to provide an excellent enhancer for an osteogenesis accelerator that can enhance the activity of BMP as an osteogenesis accelerator. Another object of the present invention is to provide a method of screening for a novel enhancer for an osteogenesis accelerator.The present invention relates to an enhancer for an osteogenesis accelerator, which comprises a compound having a TGF-β selective inhibitory activity as an active ingredient, the enhancer being administered with an osteogenesis accelerator containing BMP as an active ingredient either simultaneously or sequentially, and to a method of screening for an enhancer for an osteogenesis accelerator, comprising using a TGF-β inhibition as a measure for discovering the enhancer.